Supply of Coloxyl with Senna Film Coated Tablets by Aspen Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989 (the Act) was enacted to regulate the supply of therapeutic goods in Australia, aiming to ensure their safety, quality, and efficacy. This Act was introduced to address the need for a comprehensive regulatory framework governing the provision of medical products, including drugs, medical devices, and other health-related items. The Act empowers the Therapeutic Goods Administration (TGA) to oversee the importation, manufacture, supply, and advertising of therapeutic goods, ensuring they meet the required standards for public health and safety. The policy objective of the Act is to protect the health and safety of the Australian public by ensuring that therapeutic goods available in the market are of acceptable quality and do not pose any undue risks to consumers. The Gazette, C2013G00076, issued on 11 December 2012, is a notification by Mayada Kayali, a delegate of the Secretary to the Department of Health and Ageing, providing consent for Aspen Pharma Pty Ltd to supply specific pharmaceutical products that do not fully comply with the requirements of Therapeutic Goods Order No. 78. This consent is granted under sections 14 and 14A of the Act and is subject to specific conditions, including the content limits for sennosides and docusate sodium in the finished product specifications. This measure ensures that the products remain within safe and effective parameters, despite the minor deviations from the standard specifications, thereby maintaining the overall integrity of the therapeutic goods supplied in the Australian market.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood. The Act applies to all persons and entities involved in the supply of therapeutic goods within Australia, including manufacturers, importers, and suppliers. It extends to all therapeutic goods, irrespective of the industry or sector in which they are used, and covers the entire supply chain from manufacturing to distribution and sale. The Act’s jurisdiction is national, applying across the Commonwealth, states, and territories of Australia. The Act allows for certain exclusions, exemptions, and thresholds, which may be detailed in the Therapeutic Goods Orders, and these can be extended or restricted through subordinate instruments. The notice issued under section 14 and 14A of the Act specifies a consent for Aspen Pharma Pty Ltd to supply particular senna-based products that do not fully comply with certain content specifications outlined in Therapeutic Goods Order No. 78, subject to prescribed conditions.

Key Provisions

The main operative sections of this legislation (section 14 and section 14A of the Therapeutic Goods Act 1989) pertain to the granting of consent by the delegate of the Secretary to the Department of Health and Ageing, Mayada Kayali, for Aspen Pharma Pty Ltd to supply specific pharmaceutical products that do not fully comply with the Therapeutic Goods Order No. 78. Specifically, these products are COLOXYL WITH SENNA FILM COATED TABLETS, AMCAL SENNA-COL film coated tablets, and GUARDIAN SENNA-COL film coated tablets. The consent is granted with specific conditions regarding the content limits of sennosides and docusate sodium in the finished products. The obligations and requirements imposed by this Act on Aspen Pharma Pty Ltd and the delegate include strict adherence to the specified conditions. The content limits for sennosides must be 90.0–110.0% at both release and expiry, while the content limits for docusate sodium must be 90.0–110.0% at expiry. Beyond these specified parameters, all other requirements of Therapeutic Goods Order No. 78 must still be met. This means that while certain flexibility is provided in terms of sennosides and docusate sodium content, the products must still meet all other regulatory standards to ensure safety and efficacy. Failure to comply with the conditions set out in this legislation could result in serious consequences. Although specific offences, penalties, or civil/criminal consequences are not detailed in the provided text, breaches of the Therapeutic Goods Act 1989 can generally lead to penalties under the Act. These penalties can include substantial fines and, in severe cases, criminal charges for individuals or corporate entities responsible for the breach. The precise penalties would depend on the nature and severity of the non-compliance, but they are designed to ensure that therapeutic goods supplied in Australia meet the required standards of quality and safety.